Recursion Appoints Dr. Ramona Doyle as Chief Medical Officer
“Ramona brings fantastic experience across a broad swath of clinical development activities. What I admire most, though, is that on top of her extraordinary intellectual horsepower and experience working in clinical development, including a program her team got to market at Genentech, she has an exceptional ability to connect to the patient,” said Recursion Co-Founder and CEO Chris Gibson, Ph.D. “She continues to practice medicine on a part-time basis, even today. That kind of experience and pragmatism for what will work and matters for trialists and patients will be key to achieving our mission of decoding biology to radically improve lives.”
Before joining Recursion, Dr. Doyle most recently served as the Chief Medical Officer at Blade Therapeutics. She has 12-plus years of experience in drug development, working in increasing roles of importance at Gilead Sciences, Genentech and Roche before serving as Vice President of the California Institute of Regenerative Medicine, a funding agency for advanced stem cell‐based therapies. Prior to her move to biotech, Dr. Doyle was on the faculty at Stanford University. She completed her medical training at the University of California, San Francisco (UCSF), graduated from Emory University School of Medicine and holds a master’s degree in physiology from the University of Oxford where she was a Rhodes Scholar.
For more information on Recursion, or to view its clinical-stage pipeline and opportunities for partners, please visit http://www.recursionpharma.com/.
Recursion’s mission is to decode biology to radically improve lives. Unraveling the exceptional complexity of biological systems and delivering the next generation of biotherapeutics at unprecedented speed and scale can only be achieved by bridging life science and technology. Recursion is a leader in digital biology, and has built an advanced ultra-high throughput wet-lab and machine learning platform. Recursion’s ability to generate proprietary, high-dimensional, multi-modal and relatable datasets of human cellular biology at massive scale, and apply advanced machine learning approaches to reveal novel biological relationships, has resulted in a target-agnostic drug-discovery engine.
Recursion has demonstrated the power of its platform to industrialize drug discovery by delivering a clinical and preclinical pipeline spanning diverse therapeutic areas, positioning Recursion as a desired partner in digitally-powered drug discovery. Recursion’s drug discovery technology, inclusive culture and multidisciplinary team attract engineers and scientists who are passionate about trailblazing the frontier of digital biology. Learn more at www.recursionpharma.com, or connect on Twitter and LinkedIn.